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Abstract: 
Cranberry juice is used routinely, especially among women and the elderly, to prevent and treat 
urinary tract infections. These individuals are likely to be taking medications concomitantly with 
cranberry juice, leading to concern about potential drug-dietary substance interactions, 
particularly in the intestine, which, along with the liver, is rich in expression of the prominent 
drug metabolizing enzyme, cytochrome P450 3A (CYP3A). Using a systematic in vitro-in vivo 
approach, a cranberry juice product was identified recently that elicited a pharmacokinetic 
interaction with the CYP3A probe substrate midazolam in 16 healthy volunteers. Relative to 
water, a cranberry juice inhibited intestinal first-pass midazolam metabolism. In vitro studies 
were initiated to identify potential enteric CYP3A inhibitors from cranberry via a bioactivity-
directed fractionation approach involving dried whole cranberry [Vaccinium macrocarpon Ait. 
(Ericaceae)], midazolam, and human intestinal microsomes (HIM). Three triterpenes (maslinic 
acid, corosolic acid, and ursolic acid) were isolated. The inhibitory potency (IC50) of maslinic 
acid, corosolic acid, and ursolic acid was 7.4, 8.8, and <10 μM, respectively, using HIM as the 
enzyme source and was 2.8, 4.3, and <10 μM, respectively, using recombinant CYP3A4 as the 
enzyme source. These in vitro inhibitory potencies, which are within the range of those reported 
for two CYP3A inhibitory components in grapefruit juice, suggest that these triterpenes may 
have contributed to the midazolam-cranberry juice interaction observed in the clinical study. 
 
Article: 
INTRODUCTION 
Dangerous interactions between medications arise frequently from one drug impairing the 
elimination of another, most commonly via inhibition of one or more cytochrome P450 (CYP) 
enzymes. Consequently, regulatory agencies recommend thorough characterization of CYP 
inhibition properties of new chemical entities, at least during preclinical development [1]. In 
contrast, CYP inhibition potential of most herbal remedies/dietary supplements is not evaluated 
prior to marketing, since such products are not regulated in the same manner as drugs, even 
though they consist of mixtures of diverse chemical entities [2]. 
 
Grapefruit juice (Citrus paradisi, Macf.) is an extensively studied dietary substance shown to 
inhibit enteric (i.e., gut) CYP3A in a mechanism-based, irreversible (so-called “suicide 
substrate”) manner [2-4]. Increased drug systemic exposure can lead to untoward effects. 
Consequently, package inserts of several drug products contain cautionary statements regarding 
concomitant grapefruit juice intake. Furanocoumarins, including bergamottin and 6′,7′-
dihydrobergamottin, have been identified as major candidate CYP3A inhibitors using various 
human-derived in vitro systems [2, 4]. A clinical study involving a “furanocoumarin-free” 
grapefruit juice and the model CYP3A substrate, felodipine, established furanocoumarins, in 
aggregate, as key mediators of the felodipine-grapefruit juice interaction [5]. These observations 
may be extended to other drugs that undergo extensive first-pass metabolism by enteric CYP3A, 
including some calcium channel antagonists (e.g., felodipine, verapamil), HMG CoA reductase 
inhibitors (e.g., simvastatin, lovastatin), and immunosuppressants (e.g., cyclosporine, 
tacrolimus). 
 
Protocols, regulations, or even general strategies to investigate interactions between drugs and 
dietary substances are in nascent stages of development [2]. Recognition of this knowledge gap 
prompted our research group to investigate potential drug-diet interactions prospectively. 
Inhibition of enteric CYP3A-mediated metabolism has been a primary focus, as dietary 
substances enter the body by the oral route and are most likely to alter drug 
absorption/elimination processes in the intestine [2]. Moreover, dietary substances used as herbal 
remedies were selected, since patients often mix folkloric and prescription medications, often 
unbeknownst to their physicians and/or pharmacists [6, 7]. Finally, we have approached drug-
diet interactions from the vantage points of both natural products and drug metabolism sciences, 
melding bioactivity-directed fractionation with in vitro, and ultimately, in vivo CYP phenotyping 
methods. This merger of disciplines should allow identification of causative ingredients, as well 
as underlying mechanisms, that contribute to clinically relevant drug-dietary substance 
interactions in a time-efficient manner. 
 
To test the aforementioned strategy, a natural products/drug metabolism approach was used to 
investigate five different cranberry juices as inhibitors of intestinal CYP3A activity [8]. 
Cranberry juice is used commonly, and often prophylactically, for urinary tract infections 
(UTIs), particularly by women and the aged. This folkloric treatment of UTIs has been ascribed 
to proanthocyanidins with A-type linkages [9], which have been shown to inhibit adhesion of 
bacterial fimbriae to uroepithelial cells (reviewed in [10]). In addition, some data have emerged 
regarding benefits of cranberry products to mitigate some cancers and vascular and dental 
diseases [11-13], likely stimulating cranberry product consumption. Yet, only a few drug-
cranberry juice interaction studies have been reported, of which results were inconclusive. For 
example, in rats, cranberry juice was as effective as grapefruit juice in enhancing systemic 
exposure of the CYP3A substrate nifedipine [14]. Alternatively, a clinical study involving a 
different CYP3A substrate (cyclosporine) and cranberry juice indicated no interaction [15]. 
Similarly, a separate clinical study reported that cranberry juice had no effect on the 
pharmacokinetics of the CYP3A probe substrate midazolam [16]. Although caveats to these 
studies were discussed previously [8], until a year ago, the literature suggested that cranberry 
juice has a drug interaction liability for rats, but not humans, thus having no clinical concerns. 
While these inconsistencies may demonstrate a lack of a drug-cranberry juice interaction, an 
alternative explanation, as described and demonstrated [8], is that inherent variability in chemical 
constituents in study materials could lead to disparate results. Similarly, inconsistency in study 
materials has been cited as a reason why studies of clinical benefits of cranberry have been 
inconclusive [17]. Indeed, as reported by our research group [8], a commercial product was 
identified that showed a significant interaction with midazolam via both in vitro assays and a 
proof-of-concept clinical study. 
 
Inhibition of enteric CYP3A by some cranberry juices suggests a potential for pharmacokinetic 
interactions with medications that undergo extensive intestinal first-pass metabolism by CYP3A. 
To identify potential intestinal CYP3A inhibitory constituents from cranberry in vitro, dried 
whole cranberries [Vaccinium macrocarpon (Ericaceae)] were carried through a bioactivity-
directed fractionation approach involving midazolam and human intestinal microsomes (HIM). 
Three compounds were characterized, and IC50 values were determined using HIM and 
recombinant CYP3A4. 
 
MATERIALS AND METHODS 
Materials and Instrumentation 
HPLC-grade solvents were purchased from Burdick & Jackson (Muskegon, MI, USA). HIM 
were prepared previously from the jejunal portion of a donor small intestine [18]. Baculovirus-
insect cell-expressed CYP3A4 (supplemented with cDNA-expressed reductase) and 1′-
hydroxymidazolam were purchased from BD Biosciences (San Jose, CA). Midazolam, 
alprazolam, ketoconazole (>99% pure), NADPH, and formic acid were purchased from Sigma-
Aldrich (St. Louis, MO). All NMR experiments were performed in CDCl3 with TMS as an 
internal standard on a Varian Unity INOVA-500 instrument using a 5 mm broad-band inverse 
probe with z-gradient. HRMS spectra were acquired on an Agilent 6220 TOF mass spectrometer 
with a dual APCI/ESI ionization source. Samples (dissolved in CH2Cl2) were injected directly 
into the mass spectrometer at a flow rate of 0.6 mL/min; a two component internal reference 
standard was used to achieve <5 ppm accuracy. Flash chromatography was accomplished with a 
CombiFlash Companion flash chromatography system (Teledyne-Isco; Lincoln, NE, USA), and 
reverse phase-HPLC was carried out on Varian Prostar HPLC systems (Walnut Creek, CA, 
USA), both as described in detail previously [19]. The evaporative light scattering detector 
(ELSD) used for comparisons between purchased and isolated maslinic acid was a Varian 380-
LC. 
 
Plant material 
Whole, dried cranberries [Vaccinium macrocarpon Ait (Ericaceae)] were acquired by Botanical 
Liaisons, LLC of Boulder, Colorado, U.S.A. on November 6, 2004 and identified by Trish 
Flaster. A voucher specimen (JW2006) was archived at Botanical Liaisons, LLC. A high 
resolution digital image of the voucher (NCU 577707) was deposited in the Herbarium of the 
University of North Carolina at Chapel Hill. 
 
Extraction, Isolation and Characterization 
Whole, dried cranberries were ground to a powder using a MicroHammerMill IV milling 
machine (Glen Mills, Clifton, NJ) and processed in a manner similar to a previous study with 
cranberry juices [8]. Briefly, the powder (817 g) was stirred in MeOH at rt (5 L, 60 h) and then 
filtered. The solvent was evaporated under reduced pressure to generate a MeOH extract, which 
was partitioned between MeOH:H2O:hexane (9:1:10) to generate the hexane and aqueous MeOH 
fractions. The aqueous MeOH fraction was concentrated under reduced pressure and partitioned 
with CHCl3:MeOH:H2O (4:1:5) to generate the CHCl3 fraction and the aqueous fraction 1. The 
aqueous fraction 1 was partitioned with n-BuOH:H2O (1:1) to generate the n-BuOH fraction and 
the aqueous fraction 2. 
 
The hexane fraction (7.83 g) was dried onto Celite and subjected to column chromatography 
over silica gel 60 (~500 g; 70-230 mesh, Merck, Darmstadt, Germany) via a stepwise gradient 
that initiated with 100% hexane to 100% CHCl3 to 40% MeOH in CHCl3. Over 50 fractions 
were generated that were combined into 17 pools (labeled 1 through 17) based on similarity on 
TLC (silica gel 60 F254 plates, 0.25 mm thickness) visualized with vanillin-sulfuric acid in 
EtOH. Pool 13 (335.6 mg) was a single compound (purity described below) and was 
characterized as ursolic acid (3β-hydroxyurs-12-en-28-oic acid; 1; Figure 1) by a suite of NMR 
experiments including 1H, 13C, COSY, HSQC, and HMBC; these data were in excellent 
agreement with the literature [20]. Furthermore, 1 (C30H48O3) was subjected to HRMS, where 
an ion for [M-H]- and corresponding to C30H47O3 was observed (m/z = 455.3544 vs 455.3525; 
observed vs calculated). Pools 14 and 15 were combined (233 mg) and separated further with the 
flash chromatography system on silica gel (4 g) using a gradient from hexane to ethyl acetate. 
New fractions were combined into six pools (labeled A-F) based on the aforementioned TLC 
protocol. Pool D (15 mg) was dissolved in DMSO and separated further by reverse phase 
preparatory HPLC with a Synergi Max-RP 80 C12 column (4 μm, 250 × 21.2 mm; Phenomenex, 
Torrance, CA, USA) using an isocratic system of 88:12 MeOH:H2O (19 mL/min) to isolate 
another aliquot of 1 (1.8 mg). In total, 337.4 mg of 1 were isolated, and purity was >99% based 
on analytical HPLC with a diol column (YMC-Pack Diol-120NP, 5 μm, 250 × 4.6 mm; Waters; 
Milford, MA, USA) using a gradient from 40:60 to 80:20 ethyl acetate:hexane over 30 min at a 
flow rate of 1 mL/min. 
 
Figure 1: Structures of the CYP3A inhibitory compounds isolated from cranberry. 
 
 
The chloroform fraction (6.44 g) was dried onto Celite and subjected to column chromatography 
over silica gel 60 (~400 g) with a stepwise gradient of 100% CHCl3 up to 30% MeOH in CHCl3. 
Fractions were analyzed by TLC and combined into 10 pools (labeled 1 through 10). Pools 6 and 
7 were combined (224 mg) and separated further with the flash chromatography system on silica 
gel (12 g) using a gradient from hexane to ethyl acetate. Based on TLC profiles, seven new pools 
were generated (labeled A through G). Pools B, C, and D were combined (134 mg), dissolved in 
DMSO, and separated further by reverse phase preparatory HPLC (YMC ODS-A 5 μm, 250 × 20 
mm) using an isocratic system of CH3CN:H2O (60:40) (10 mL/min); 100% MeOH was eluted at 
the end to wash out any residue. This purification was carried out in two separate batches, 
generating four fractions on the initial separation (labeled 1-1 through 1-4) and two fractions on 
the second separation (labeled 2-1 and 2-2). Fractions 1-3, 1-4, and 2-2 were combined (50 mg), 
dissolved in DMSO, and purified further by reverse phase preparatory HPLC using the 
aforementioned C12 column via an isocratic system of 77:23 MeOH:H2O (19 mL/min) to isolate 
maslinic acid (2α,3β-dihydroxyolean-12-en-28-oic acid; 2) (6.6 mg) and corosolic acid (2α,3β-
dihydroxyurs-12-en-28-oic acid; 3) (21.1 mg). Each compound was analyzed by HPLC using a 
Synergi Max-RP 80 C12 column (4 μm, 250 × 4.6 mm) via an isocratic solvent system of 80:20 
MeOH:H2O (1 mL/min) and was >90% and >99% pure, respectively. Both compounds were 
characterized using the aforementioned suite of NMR experiments; data were in excellent 
agreement with the literature [21-23]. These data were supported by HRMS measurements. 
Compound 2 (C30H48O4) yielded an ion for [M-H]-, corresponding to C30H47O4 (m/z = 471.3493 
vs 471.3474; observed vs calculated); compound 3 (C30H48O4) yielded an ion for [M-H]-, 
corresponding to C30H47O4 (m/z = 471.3491 vs 471.3474, observed vs calculated). Since a 
limited amount of compound 2 was isolated, two different HPLC conditions were used to verify 
the identity of 2 with a purchased reference standard of maslinic acid (lot 184071-6; Cayman 
Chemical, Ann Arbor, MI. USA). One analysis was accomplished on a C18 column (YMC ODS-
A 5 μm, 150 × 4.6 mm) using an isocratic solvent system of CH3CN:H2O (60:40) at a flow rate 
of 1.0 mL/min. Another analysis was conducted via the aforementioned C12 column using an 
isocratic solvent system of MeOH:H2O (80:20) at a flow rate of 1.0 mL/min. Peaks were 
detected via PDA at 203 nm and via ELSD. Isolated maslinic acid (2) and the reference standard 
had the same retention times in both systems and co-eluted when mixed together; Figures 4a and 
4b (Supporting Information) display these data as observed via ELSD under both conditions. 
 
Testing of Cranberry Fractions for Inhibition of Intestinal CYP3A Activity 
Fractions from whole cranberries were tested as inhibitors of intestinal CYP3A activity in vitro 
using midazolam and HIM as described [8]. The final concentration of each component in 
incubation mixtures was as follows: midazolam, 4 μM; HIM, 0.05 mg/mL; cranberry fraction, 
0.05-50 μg/mL; potassium phosphate buffer, 0.1 M (pH 7.4), containing magnesium chloride 
(3.3 mM); and NADPH, 1 mM. The CYP3A inhibitor, ketoconazole (1 μM), was used as a 
positive control in place of cranberry fraction. Vehicle control incubation mixtures contained 1% 
MeOH in place of cranberry fraction or ketoconazole. Incubation mixtures were analyzed for 1′-
hydroxymidazolam by HPLC/MS-MS as described [24]. 
 
Determination of IC50 for Triterpenes using HIM and Recombinant CYP3A4 
Reference maslinic acid and isolated corosolic acid were reconstituted with MeOH to yield a 
working concentration of 10 mM. Ursolic acid was reconstituted with MeOH to yield a working 
concentration of 5 mM. Incubations with HIM (0.05 mg/mL) or recombinant CYP3A4 
(rCYP3A4) (10 pmol/mL) were prepared as described above, only cranberry fraction was 
replaced with triterpene (1-80 μM); vehicle control incubation mixtures contained 1% MeOH in 
place of triterpene or ketoconazole. 
Data analysis 
Initial estimates of apparent IC50 values were derived from linear regression of velocity vs. 
natural logarithm of triterpene concentration data. Apparent IC50 values were determined by 
fitting either of the following equations with untransformed data using WinNonlin (v5.2.1, 
Pharsight, Mountain View, CA):  
 
 
(Eq. 1) 
 
(Eq. 2) 
 
where S denotes concentration of substrate (midazolam); v0 and v denote velocity of 1′-
hydroxymidazolam formation in the absence and presence of triterpene, respectively; and h 
denotes the Hill coefficient. The best-fit equation was assessed from visual inspection of 
observed vs predicted data, randomness of residuals, Akaike information criteria, and standard 
errors of parameter estimates. 
 
Statistical Analysis 
Data are presented as means ± standard deviations of triplicate determinations unless indicated 
otherwise. IC50 values are presented as estimates ± standard error of the estimates. 
 
RESULTS AND DISCUSSION 
Previously, an in vitro-in vivo approach involving HIM, the CYP3A probe substrate midazolam, 
and five cranberry juice products identified a cranberry juice that inhibited enteric CYP3A 
activity in human volunteers, increasing midazolam AUC by 30% relative to water (p<0.001) 
[8]. These observations spurred bioactivity-directed fractionation of cranberries, using an in vitro 
bioassay, to identify candidate CYP3A inhibitory constituents. Dried whole cranberries, rather 
than the clinical test juice, were utilized for several pragmatic reasons. First, it was possible to 
acquire large amounts of cranberries and to deposit an herbarium voucher specimen, thereby 
tracing the study materials back to the site of growth and harvest; as has been noted, herbarium 
vouchers often are missing from investigations of herbal medicines [25]. Moreover, cranberry 
juices are supplemented routinely with juices of other fruits, added sugars, and preservatives [8], 
any of which could confound interpretation of results. Finally, extracts and fractions of 
cranberries could be evaluated at 50 and 5 μg/mL, concentrations consistent with other natural 
product investigations. In short, the study was designed to mimic as closely as possible 
bioactivity-directed fractionation studies used commonly for discovery of new anticancer and/or 
antibiotic leads, but via monitoring of inhibition of CYP3A activity in vitro. 
 
Of the four initial fractions generated from whole cranberry, the hexane- and chloroform-soluble 
fractions were the most potent, inhibiting intestinal CYP3A activity by approximately 40% and 
80%, respectively, at 50 μg/mL (Figure 2). The hexane-soluble fraction, which was the most 
potent in the previous study of cranberry juices [8], was separated to generate 17 subfractions. 
Some of the more polar subfractions, particularly 13-15, were the most potent, inhibiting activity 
by ≥70% at 50 μg/mL (Figure 2). Subfraction 13 consisted of one major compound by HPLC 
that was characterized as ursolic acid (1; Figure 1) via a suite of NMR experiments. Fractions 14 
and 15 were purified further, yielding six pools (labeled A-F; Figure 2), and another aliquot of 1 
was isolated from pool D. Other inhibitory pools (i.e., pools E and F) were examined as well 
(data not shown), and 1 was presumed to be the major constituent, likely responsible for the 
observed in vitro CYP3A inhibitory properties. 
 
Figure 2: Bioactivity-directed fractionation of cranberry, and inhibitory effects on intestinal 
CYP3A activity in vitro, as measured by midazolam 1′-hydroxylation. Circled fractions were 
carried forward in purification processes. Bars denote means of duplicate (more ...) 
 
 
The parent chloroform-soluble fraction was separated in a similar manner to generate 10 
subfractions (labeled 1-10; Figure 2). Subfractions 6 and 7 were the most potent (>90% 
inhibition at 50 μg/mL) and were purified further to yield seven subfractions (labeled A-G) 
whose inhibition at 50 μg/mL was below the limit of quantification. Two rounds of preparatory 
HPLC using both C18 and then C12 columns yielded two major compounds from subfractions 1-
3, 1-4, and 2-2 (Figure 2), which were characterized as maslinic acid (2) and corosolic acid (3) 
using a suite of NMR experiments (Figure 1). Since a limited amount of 2 was isolated, a 
standard was purchased for the in vitro assays; isolated and purchased compounds were identical, 
as characterized by HPLC (Supporting Information; Figures 4a and 4b). 
 
Inhibitory potencies for compounds 1-3 were evaluated in vitro using HIM and rCYP3A4. 
Compounds 2 and 3 were approximately equipotent. With HIM, IC50 values were 7.4 and 8.8 
μM, respectively; with rCYP3A4, values were 2.8 and 4.3 μM, respectively (Table 1 and Figure 
3). A robust estimate of IC50 for 1 was not recoverable with either enzyme source, most likely 
due to the sharp decrease in extent of inhibition between 0 and 1 μM (Figure 3). As such, data 
are displayed as bar graphs; by visual inspection, the IC50 was approximated at 10 μM for both 
HIM and rCYP3A4 (Table 1). 
 
Table 1: IC50 values* (μM) for triterpenes using human intestinal microsomes (HIM) or 
recombinant cytochrome P450 3A4 (rCYP3A4) as the enzyme source. Ketoconazole (1 μM) was 
used as a positive control for CYP3A inhibition and inhibited activity by >90%. 
Compound HIM rCYP3A4 
Ursolic acid (1) <10 <10 
Maslinic acid (2) 7.4 ± 0.5 2.8 ± 0.2 
Corosolic acid (3) 8.8 ± 0.9 4.3 ± 0.3 
*Values denote means ± SEs of parameter estimates. 
 
Figure 3: IC50 curves for ursolic acid (1), maslinic acid (2), and corosolic acid (3) in HIM (A 
and B) and in rCYP3A4 (C and D). Symbols/bars and error bars denote means and SDs, 
respectively, of triplicate incubations. 
 
In summary, a bioactivity-directed fractionation study of cranberries led to isolation of three 
triterpenes (1-3), all of which inhibited enteric CYP3A activity in vitro. The appreciable 
potencies for 1-3 toward enteric CYP3A activity suggest that they could have contributed to the 
midazolam-cranberry juice interaction observed in healthy volunteers [8], although their relative 
concentration and solubility in various products could preclude the generality of this observation. 
Regardless, as isolated compounds, their IC50 values are in the range of, or somewhat higher, 
than IC50 or Ki values determined previously for bergamottin (6->100 μM) and 6′,7′-
dihydroxybergamottin (<1-5 μM), two furanocoumarins and CYP3A inhibitors in grapefruit 
juice [26, 27], supportive of a bioactivity-directed fractionation approach for the identification of 
CYP3A inhibitors. Studies are underway to determine inhibition potency of 1-3 in Caco-2 cell 
monolayers modified to express CYP3A4 [28] and to measure their concentration in commercial 
products; NAPRALERT indicates that at least two of these compounds (1 and 2) have been 
reported in either cranberry or related species of Vaccinium. 
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